Last edition
News about
Parexel Launches Biotech Incubator for Early-stage Innovators
Parexel has launched the Parexel Biotech Incubator to support early-stage therapeutics companies with clinical development expertise and strategic resources. The initiative includes a founding partnership with Cape Fear BioCapital to connect incubator to a seed-stage venture partner.
Antengene Licenses ATG-106 to K2 Therapeutics in Strategic Deal
Antengene has granted K2 Therapeutics exclusive global rights to develop and commercialise ATG-106 outside Greater China under a strategic licensing agreement that also includes an option for an undisclosed bispecific T-Cell Engager (TCE).
BioArctic and Lilly Sign Collaboration and Research Agreement for BrainTransporter-Based Therapy
BioArctic and Lilly have entered a research and collaboration agreement to combine a Lilly compound with BioArctic’s BrainTransporter technology. BioArctic will receive a USD 30 million upfront payment under the deal.
Shilpa Biologicals has launched PartnerPower, a proprietary platform offering real-time visibility into process development and Good Manufacturing Practice (GMP) manufacturing, setting a new benchmark for transparency in CDMO operations.
Insilico Medicine and SK Biopharmaceuticals have entered an Artificial Intelligence (AI)-powered drug discovery collaboration worth up to USD 2.5 billion to develop innovative therapies for neuroimmune disorders.
Boehringer Ingelheim has initiated 3 phase 3 oncology trials, including DAREON-Lung-1 and DAREON-NEC-1, to evaluate obrixtamig as a DLL3 biomarker-guided treatment approach for hard-to-treat cancers.
CureGene Doses First Patient in Pivotal US Trial of Evategrel
CureGene achieves first participant dosed in US pivotal trial for Evategrel (CG-0255), a best-in-class antiplatelet drug, accelerating global commercialisation.
Merck's Tulisokibart Met Primary and Key Secondary Endpoints in Phase 3 ATLAS-UC Induction
Merck’s tulisokibart achieved both primary and key secondary endpoints in the phase 3 ATLAS-UC induction study, demonstrating significant efficacy in patients with moderately to severely active Ulcerative Colitis (UC).
Sanofi Names Paulo Fontoura to Lead Global R&D Operations
Sanofi has appointed Paulo Fontoura as Global Head of Research and Development (R&D). Based in Paris, he will join the Executive Committee and report directly to CEO Belén Garijo.
RedHill Biopharma Closes Private Placement of up to USD 19.4 Million
RedHill Biopharma has closed a private placement worth up to USD 19.4 million, including USD 6 million upfront and up to USD 13.4 million in additional proceeds from the full exercise of warrants.
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy